AFFX Affymetrix, Inc.

Global genetic products developer and manufacturer Affymetrix, Inc. (AFFX) recently announced a world-wide collaboration with Leica Microsystems, a leading manufacturer of microscopes and other scientific instruments. The collaboration will allow QuantiGene ViewRNA ISH Tissue Assay produced by Affymetrix to undergo automation on the Leica BOND RX staining platform for research applications.

Affymetrix is rigorously implementing its strategy of improving its Panomics Solution product lines. Last month, Affymetrix announced a global distribution agreement with ScreenCell, a medical devices company which specializes in isolating rare circulatory cells.

Management at Affymetrix believes that collaboration with Leica will bring out the true potential of single-copy RNA analysis. It also believes that the partnership will validate unique companion tests and stimulate the exposition of new drugs.

The company is expanding its customer base through new product launches and strategic alliances. Moreover, it is pursuing a number of strategies (including expansion into new markets) aimed at its top line.

Management at Leica Microsystems is optimistic about improving standard and quality of patient care after the collaboration. The partnership will support the development and discovery process for new drugs. It will also reduce time taken for research and associated costs, thereby providing new treatment ahead of expectations.

The company’s QuantiGene product portfolio provides quantitative gene expression analysis. With automation of the QuantiGene ViewRNA ISH Tissue Assay on the Leica BOND RX, researchers will have an automated solution for drug discovery, translation research, and development of new companion diagnostic tests for personalized medicine on a regular basis.

Affymetrix will provide the complete staining kit comprising the QuantiGene ViewRNA staining protocol and the Leica BOND RX. The QuantiGene ViewRNA ISH Tissue Assay on the Leica BOND RX staining platform kit will serve researchers in the discovery market starting from the third quarter of 2012.

Affymetrix is a leading provider of microarray-based products and services to the global research community. Along with Illumina Inc. (ILMN), it is one of the two major providers of microarray technologies, primarily used in the field of genetic research.

 
AFFYMETRIX INC (AFFX): Free Stock Analysis Report
 
ILLUMINA INC (ILMN): Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research